Host-specific differences in the physiology of acid secretion related to prostaglandins may play a role in gastric inflammation and injury

Ireneusz T. Padol and Richard H. Hunt

Intestinal Disease Research Programme, McMaster University, Hamilton, Ontario, Canada

Submitted 12 August 2004 ; accepted in final form 18 January 2005

ABSTRACT

Immune mediators are involved in strain-specific manifestations of Helicobacter pylori infection, and the type of immune response is associated with production of PGE2, which in turn influences gastric acid secretion. Acid secretion plays a pivotal role, not only in the pattern of H. pylori-induced gastritis and its consequences, but also in nonsteroidal anti-inflammatory drug (NSAID)-induced gastropathies. Mice and their transgenic modifications are widely used in Helicobacter and eicosanoid research. Using [14C]aminopyrine accumulation and pylorus ligation, we aimed to study acid secretion in gastric gland preparations from the commonly used strains of BALB/c and C57BL/6 mice. We found that PGE2 does not inhibit acid secretion in gastric glands from C57BL/6 mice, in contrast to the expected antisecretory effect of PGE2 observed in BALB/c mice. In BALB/c mice the effect of histamine and carbachol was reduced by PGE2, whereas in C57BL/6 mice dose-response curves to these secretagogues were not affected. EP3 receptors are not involved in acid secretion in C57BL/6 mice, as confirmed by significantly lower expression of mRNA for the EP3 receptor. These contrary findings are important to the interpretation of the antisecretory role of eicosanoids in BALB/c and C57BL/6 mouse strains and the involvement of prostanoids in the etiology of Helicobacter-induced inflammation and NSAID-induced gastropathies. We propose that the lack of antisecretory effect of PGE2 observed in C57BL/6 mice could reflect the extent of Helicobacter-induced inflammation and status of acid secretion in response to anti-inflammatory drugs.

gastric glands; gastric acid; mouse; prostaglandin E2; BALB/c; C57BL/6; histamine; carbachol; somatostatin; omeprazole; ranitidine; butaprost; sulprostone; misoprostol; EP3 receptor


ACID SECRETION PLAYS A PIVOTAL role in the etiology of many esophageal, gastric, and duodenal disorders. The secretory state of the gastric mucosa may be associated with a wide range of morphological changes, including Helicobacter-induced atrophic gastritis and nonsteroidal anti-inflammatory drug (NSAID)-induced erosions and ulcer, in animal models and in humans. Mouse models have recently been accepted into the mainstream of research into gastric pathology, inasmuch as they rely on the availability of transgenic techniques and an extensive knowledge of the immune system. Aminopyrine accumulation is a reliable method for studying acid secretion in human (21) and animal parietal cells or gastric gland preparations (3), and we recently extensively characterized the pharmacology of acid secretion in the mouse (28) to meet the demand for knowledge in this area. The mouse model has been widely used in the study of Helicobacter-induced gastritis and revealed strain-dependent patterns (20). With the use of Helicobacter felis-infected BALB/c mice, it was found that local acid production is critical for the distribution of Helicobacter species in the stomach (7, 19). In these mice, H. felis is predominantly restricted to the antrum and cardia and invades the body only with concomitant pharmacological acid suppression. In contrast, H. felis infection in C57BL/6 mice tends to colonize the secretory oxyntic mucosa of the corpus and contribute to the reduction in the number of parietal cells and subsequent development of gastric atrophy (8, 10, 29). This strain-specific difference between mice in response to Helicobacter pylori infection has been attributed to the predominant type of immune response, T helper (Th) type 2 (Th2) in BALB/c mice and type 1 (Th1) in C57BL/6 mice (24, 35). Some studies have suggested that clearance of bacteria is related to host genetic differences between strains (13).

PGE2 and its action through the EP3 receptor comprise the predominant prostanoid involved in the inhibition of acid secretion in animal models (34, 38). In rabbit parietal cells, PGE2 inhibits histamine- and carbachol-stimulated acid secretion, and preincubation with indomethacin increases aminopyrine accumulation (6). Moreover, PGE2 significantly inhibits acid secretion in human parietal cells, thus supporting its role as a local regulator of acid secretion (12). However, the role of PGE2 in the mechanisms governing gastric pathology may not be limited to its antisecretory function. It was shown in H. pylori-infected BALB/c mice that endogenous PGE2 may mediate suppression of the Th1-type immune response with a shift toward a Th2 response (5). Similar suggestions have been proposed by Kuroda and Yamashita (15), who found higher levels of PGE2 produced by macrophages from BALB/c than from C57BL/6 mice. These important findings implicate prostanoids and, thus, physiological changes in acid secretion with the type of immune response. The link between prostaglandin metabolism and H. pylori infection was suggested by showing that secretory phospholipase A2 is reduced in H. felis-infected C57BL/6 mice and leads to increased proliferation and apoptosis, in contrast to BALB/c mice (27, 37).

Because of a clear relation between acid secretion, type of immune response, mucosal prostanoids, and host-specific differences in gastric pathology, we decided to study the pharmacology of acid secretion in strains of mice that are widely used in these areas of research, namely, BALB/c and C57BL/6. We placed emphasis on the role of prostanoids as an important endogenous antisecretory mediator of acid secretion, which may play a decisive role in Helicobacter-induced inflammation as well as in NSAID-induced injury.

MATERIALS AND METHODS

Animals

Six- to eight-week-old BALB/c and C57BL/6 mice (Charles River, St. Constant, PQ, Canada) were kept under standard housing conditions (21–23°C, 40–50% humidity, and 12:12-h light-dark cycle) and fed Purina Lab Rodent Chow for up to 12 wk. Five mice from each strain were used in each experiment. Mice were fasted for 24 h (water ad libitum) and killed by cervical dislocation. The stomachs were quickly removed, opened along the lesser curvature, and placed in oxygenated 37°C PBS buffer at pH 7.3. Use of animals was approved by the Animal Research Ethics Board at McMaster University.

Preparation of Gastric Glands From Mice

The gastric gland preparation was performed as we previously described (28). Briefly, the gastric mucosa was scraped off the underlying muscle with a scalpel blade, pooled separately from each mouse strain, and washed twice (~200 g for 5 min) in PBS. The mouse gastric mucosa was enzymatically digested at 37°C for 45 min, and the conditions were identical for both mouse strains. After enzymatic digestion, the gastric glands were passed through a nylon mesh to separate the debris and the undigested remains of the gastric mucosa. The preparation was then washed three times (~200 g for 5 min) in enzymatic buffer that contained neither collagenase nor trypsin inhibitor. Finally, the preparations were resuspended in 25 ml of incubation medium containing 2 mg/ml of BSA, 2 mg/ml of glucose, 1 mM MgSO4, and a total of 2 mM CaCl2. Therefore, the yield of the preparation from each mouse strain was 25 ml with ~10 µl of packed gastric glands per milliliter.

Measurement of Acid Secretion in Mouse Gastric Glands

Acid secretion was measured by accumulation of weak base [14C]aminopyrine as described by Berglindh (3), with some modifications (28). Briefly, the experiment was carried out in closed 1.5-ml Eppendorf tubes containing 0.5 ml of resuspended gastric glands with added secretagogue (e.g., 0.01 mM carbachol or 0.1 mM histamine) and antisecretory compound (e.g., PGE2, somatostatin, omeprazole, or ranitidine). The tubes representing basal acid secretion did not contain histamine or carbachol. Also, 20 µl, equal to 0.25 µCi of [14C]aminopyrine, were added to the tubes, and the incubation was carried out at 37°C for 60 min with rotation. Therefore, all reagents tested, including [14C]aminopyrine, were added at the same time and were incubated with the gastric glands. The tubes were spun, the supernatant was aspirated, and the pellets were counted in a scintillation counter (model LS 5801, Beckman). Each sample was tested in triplicate within each individual experiment. Each experiment was repeated in different gland preparations from each mouse strain, and this replication is represented by the number of individual experiments (n). Basal and carbachol- and histamine-stimulated aminopyrine uptake was 2,056 ± 784, 12,316 ± 4,419, and 38,772 ± 16,193 disintegrations/min, respectively. Data are presented as percentages of maximal response for each secretagogue.

Measurement of Acid Secretion in the Mouse In Vivo

Acid secretion was measured in vivo by means of pylorus ligation (31). Briefly, mice were fasted for 24 h (with water ad libitum), and, under anesthesia, a midline incision was made in the abdomen. A pyloric ligature of silk was placed, and the wound was closed with sutures. Drugs such as carbachol and misoprostol were administered subcutaneously at the time of ligation; then the animals were allowed to awaken from anesthesia, were placed in metabolic cages, and received nothing for the next 3 h. After that time, the mice were anesthetized again, a ligature was placed, this time at the esophageal junction, and the stomachs were removed. A small incision was made, through which the contents of the stomach were collected and centrifuged, and the volume of gastric juice was recorded and sampled for acidity by titration of 50-µl samples to pH 7.0 with 0.1 M NaOH. Total acid output was calculated and expressed as microequivalents of HCl per 100 g body wt.

RT-PCR of the EP3 Receptor From Mouse Gastric Mucosa

RNA isolation from mouse gastric mucosa. Samples of oxyntic mucosa scraped from the stomachs of each strain of mice were placed in tubes containing 1 ml of RNALater (Ambion), designated samples A and B, and the following procedures were carried out in a blinded fashion. Tissue samples were separated from RNALater using a tissue sieve and weighed: 68.8 mg (sample A) and 28.8 mg (sample B). Then samples were disrupted and homogenized for 45 s using a Polytron at setting 6. Total RNA was isolated using the Qiagen RNeasy Midi system according to the manufacturer's instructions. Total RNA was eluted using nuclease-free sterile water, and the final concentration was determined by spectrophotometric analysis: 706.8 ng/µl (sample A) and 326.8 ng/µl (sample B). RNA samples were stored overnight at –80°C.

RT reaction and PCR amplification of EP3. cDNA was obtained from the RNA samples using RT Omniscript in the presence of oligo(dT) primers to select for mRNA. Five sets of PCR primers were designed using Primer3 software (Table 1). The primer pairs were screened using mouse genomic DNA amplification was carried out as follows: 30 cycles of 92°C for 1 min, denaturation at 52°C for 1 min, annealing, and extension at 72°C for 1 min.


View this table:
[in this window]
[in a new window]
 
Table 1. PCR primers

 
Chemicals

Histamine, carbachol, and indomethacin were purchased from Sigma; PGE2, butaprost, sulprostone, and misoprostol from Cayman Chemical; and somatostatin from Cambridge Research Chemicals. All chemicals were dissolved in water, with the exception of PGE2, butaprost, and sulprostone, which were dissolved in DMSO. Indomethacin and omeprazole were dissolved in water with addition of NaHCO3 (0.6 mg/ml). [14C]aminopyrine had a specific activity of 115 mCi/mmol and was purchased from Amersham Pharmacia Biotech. All other chemicals were purchased from Sigma.

Statistical Analysis

Data were calculated as percentage of maximal response of aminopyrine uptake to various stimulants, and n represents the number of gland preparations for which each data point was tested in triplicate. Values are means ± SE. The significance of differences was tested by ANOVA with Bonferroni's post hoc examination of means and considered statistically significant if P < 0.05.

RESULTS

The enzymatic digestion of gastric mucosa from BALB/c and C57BL/6 mice resulted in the preparation of functional gastric glands with the ability to secrete acid for up to 5 h. In preparations from both strains, nearly all (>95%) cells in the glands were viable as measured by trypan blue exclusion. The yield from gastric glands was the same for both strains, and all data are expressed as percentage of maximal response to each specified secretagogue: histamine or carbachol.

Construction of dose-response curves revealed that the histamine response curve in gastric glands from C57BL/6 mice is shifted to the left compared with that from BALB/c mice (ED50 = 2.2 ± 1.6 and 7.4 ± 1.2 µM, respectively, P < 0.05), with 0.1 mM giving the maximal response for both strains (Fig. 1A). For carbachol, there was no statistically significant shift in dose-response curves in glands from C57BL/6 mice; however, there was a distinct difference in the maximal response to carbachol between the strains (Fig. 1B). In C57BL/6 and BALB/c mice, the maximal response to carbachol was observed at 1.0 and 10.0 µM, respectively.



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 1. Effect of secretagogues on acid secretion in a gastric gland preparation from BALB/c and C57BL/6 mice measured by [14C]aminopyrine accumulation and expressed as percentage of maximal response. A: histamine (Hist, n = 9–10). B: carbachol (Carb, n = 10–11). Values are means ± SE.

 
The experiments with each secretagogue were repeated in the presence of 10.0 µM indomethacin, which resulted in overlapping dose-response curves (data not shown). These experiments excluded the possibility that endogenous prostaglandins are involved in the inhibition of acid secretion in our strain-specific gastric gland preparations.

PGE2 inhibited histamine-stimulated acid secretion to a maximal effect of 60% at 1.0 µM in glands from BALB/c mice but had no effect at any concentration tested in glands from C57BL/6 mice (Fig. 2A). Similarly, for the carbachol-stimulated response, 10 µM PGE2 inhibited acid secretion up to 36% in glands from BALB/c mice but not at any concentration in glands from C57BL/6 mice (Fig. 2B). Carbachol dose-response curves were not affected by the presence of 10 µM ranitidine, excluding the possibility of involvement of histamine in these preparations (data not shown). The differences were consistent in all experiments with PGE2 in both strains of mice, and the inhibitory effects were always present in glands from BALB/c mice and absent in glands from C57BL/6 mice. To eliminate any possibility of artifact, we have cross-switched the preparations, digestion flasks, sequence of tubes, and sequence of procedures, including performing experiments in a blinded fashion. The ability of PGE2 to inhibit secretagogue-stimulated acid secretion always followed the mouse strain origin of the gastric mucosal samples and was found only in BALB/c mice.



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 2. Effect of PGE2 on maximally stimulated acid secretion in gastric glands from BALB/c and C57BL/6 mice measured by [14C]aminopyrine accumulation and inhibition and expressed as percentage of maximal response. A: 100 µM histamine in both strains (n = 11–12). B: 10 µM carbachol in BALB/c and 1.0 µM carbachol in C57BL/6 (n = 3). Values are means ± SE.

 
To investigate further this distinct difference in PGE2 results, we tested the effect of another potent endogenous antisecretory mediator, somatostatin. The dose responses to soma-tostatin were almost identical for both mouse strains (Fig. 3A). In addition, we tested the proton pump inhibitor omeprazole and the histamine H2 receptor antagonist ranitidine on histamine-stimulated acid secretion and observed distinct antisecretory dose-response curves in both mouse strains, with a trend for both drugs to be more potent in the BALB/c preparation (Fig. 3B). However, the shift to the left observed in BALB/c mice reached statistical significance only for ranitidine (ED50 = 6.1 ± 1.3 and 21.3 ± 1.6 µM, respectively, P < 0.05). Experiments with somatostatin and antisecretory drugs were done with the inclusion of control tubes containing PGE2, which as already described, again strain specifically inhibited acid secretion. Thus we further excluded the possibility of preparation artifact.



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3. Inhibition of histamine-stimulated acid secretion in gastric glands from BALB/c and C57BL/6 mice measured by [14C]aminopyrine accumulation and expressed as percentage of maximal response to 100 µM histamine. A: dose response to somatostatin (n = 5–6). B: dose response to omeprazole or ranitidine (n = 3). Values are means ± SE.

 
In the next set of experiments, we tested the effect of 1.0 µM PGE2 (maximal effect) on dose-response curves to histamine and carbachol in preparations from both mouse strains. Consistently, as with the previous results, PGE2 did not affect the dose-response curves for either secretagogue in C57BL/6 mice (Fig. 4). However, in the case of glands from BALB/c mice, 1.0 µM PGE2 again resulted in the characteristic inhibition of histamine- and carbachol-stimulated acid secretion. This PGE2-related inhibition resulted primarily in a difference in the effect of histamine and carbachol, but not in their potency (Fig. 4).



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 4. Effect of a maximal inhibitory concentration of PGE2 (1.0 µM) on dose-response curves to secretagogues in gastric glands from BALB/c and C57BL/6 mice measured by [14C]aminopyrine accumulation and expressed as percentage of maximal response. A: histamine. B: carbachol. Values are means ± SE (n = 3). CTRL, controls.

 
We have also tested the properties of the EP subtype-specific selective agonists butaprost (EP2 specific) and sulprostone (EP3 specific) and observed that only sulprostone mimicked the PGE2 inhibitory dose-response curve, and only in BALB/c mice (Fig. 5A). This experiment showed that the EP3 receptor is involved in PGE2 inhibition in mouse gastric glands from BALB/c mice. In this strain, inhibition was also related to the highest tested concentration of the EP2-specific agonist butaprost (Fig. 5A). However, neither sulprostone, butaprost, nor PGE2 had an effect on histamine-stimulated acid secretion (Fig. 5B) in glands from C57BL/6 mice, indicating that, in this setting, the EP3 receptor is not involved in this mouse strain.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 5. Effect of EP subtype-specific receptor agonists sulprostone (EP3) and butaprost (EP2) on histamine-stimulated acid secretion in gastric glands from BALB/c (A) and C57BL/6 (B) mice measured by [14C]aminopyrine accumulation and expressed as percentage of maximal histamine response. Values are means ± SE (n = 3).

 
To verify further these dichotomous findings, which we observed in the in vitro mouse model of the effect of prostaglandins on acid secretion, we tested the effect of the PGE1 analog misoprostol and a selective EP3 receptor agonist sulprostone in vivo. Misoprostol and sulprostone (50 µg/kg sc) administered at the time of pylorus ligation almost completely inhibited carbachol-stimulated acid secretion in BALB/c mice but had no significant effect in C57BL/6 mice (Fig. 6).



View larger version (21K):
[in this window]
[in a new window]
 
Fig. 6. Effect of misoprostol (50 µg/kg, dotted bars) and sulprostone (50 µg/kg, hatched bars) on carbachol (200 µg/kg, solid bars)-stimulated acid secretion in BALB/c and C57BL/6 mice measured in vivo by pylorus ligation. Data are expressed as microequivalents of HCl per 100 g body wt per 3 h. Values are means ± SE (n = 5–8).

 
To identify EP3 receptors in gastric mucosa from both mouse strains, we first screened the primers. Primer pairs EP3-1 and EP3-2 resulted in a single PCR product of the correct size using genomic DNA (Fig. 7). The EP3-2 primer pair was more efficient for PCR and was used for RT-PCR. Primer pairs EP3-3 to EP3-5 did not result in amplification of genomic DNA.



View larger version (8K):
[in this window]
[in a new window]
 
Fig. 7. Screening of primer pairs. +, PCR in the presence of mouse genomic DNA; –, negative control.

 
In RT-PCR, equal amounts of RNA from samples A and B were used for the RT reaction (6 µg). Primer pair EP3-2 was used for the subsequent PCR step. EP3 was amplified to 6.91 ng/µl by PCR of sample A and to 1.52 ng/µl by PCR of sample B. Decoding of the samples revealed that expression of message for the EP3 receptor was about five times lower in oxyntic mucosa from C57BL/6 than from BALB/c mice (Fig. 8).



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 8. RT-PCR of EP3 receptor from samples A (BALB/c), B (C57BL/6), and C (negative control).

 
DISCUSSION

Our experiments indicate host-specific differences in acid secretion in gastric glands and the pylorus-ligated mouse model. BALB/c mice have a prostaglandin-mediated antisecretory feedback loop, and C57BL/6 are "prostaglandin blind" in terms of acid secretion. These findings are important not only to understanding the role of prostaglandins in the heterogeneity of gastric acid physiology in a given population of animals but also for the unique possibility to study prostaglandin involvement in H. pylori infection and/or NSAID-induced gastropathies. Until now, investigators have not been aware of these strain-specific differences and may have drawn inaccurate conclusions from animal models or their possible clinical relevance.

Mice with targeted gene disruptions have entered the mainstream of research in the field of eicosanoids and their role in gastric physiology. A thorough review lists ≥18 different gene knockout models that are relevant to eicosanoid biology (1). However, this report does not list the wild-type or background mouse strains and lacks any suggestion that strain-specific differences in prostaglandin biology might exist. Similarly, another review focusing on the regulation of acid secretion through analysis of genetically engineered mice makes no comment on antisecretory prostaglandin pathways (30). Lack of information about acid secretion in wild-type mice may have led to the conclusion that acid secretion is maintained without involvement of cyclooxygenase-1 in mice (4). Consequently, the same study that used the C57BL/6 strain showed no effect of indomethacin and naproxen on acid secretion. Similarly, reports have concluded that prostaglandins from the cyclooxygenase-1 pathway are not involved in gastric homeostasis (17, 18). In another study with C57BL/6 mice, the authors concluded that EP1, not EP3, receptors are involved in PGE2 inhibition in indomethacin-induced gastric lesions (32). These conclusions could be misleading, because C57BL/6 mice lack a response to PGE2, as demonstrated in our study. Mapping of genes encoding for the mouse PGE receptor comes from studies in C3H/HeJ mice and cellular localization of mRNAs for receptor subtypes from ddY mice (11, 25, 33). We should be cautious, therefore, in extrapolating these findings to other mouse strains and should consider taking a multistrain approach in mouse prostanoid research. Furthermore, some of the reports on the role of prostaglandins in gastric acid secretion have been published without mention of the mouse strain used (22, 23). Our RT-PCR revealed that the strain difference we have characterized pharmacologically is related to lower expression of message for the EP3 receptor in gastric mucosa from C57BL/6 than from BALB/c mice. This may be sufficient for compromised EP3 receptor status, receptor number, and/or function on parietal cells of C57BL/6 mice and subsequent lack of PGE2 inhibitory effect on acid secretion in this strain. However, the actual status of EP3 receptors on parietal cells can only be explored by appropriate binding studies using pure populations of these cells, and this may be technically challenging. Furthermore, arachidonic acid is released from esterified precursors by the action of phospholipase A2 (16), and it is possible that levels of prostanoids are influenced by a lack of phospholipase A2 in C57BL/6 mice (14). In our BALB/c in vivo studies, misoprostol inhibited acid secretion by 97% compared with 36% in vitro, suggesting that in the intact animals central EP receptors may be involved, resulting in such an effective inhibition. This, combined with the lack of an in vivo effect of misoprostol on acid secretion in C57BL/6 mice, further suggests that a genetic component that extends beyond the gastric mucosa may be involved in this strain difference. The in vivo experiment with sulprostone, a PGE2 analog and selective agonist for EP3 receptor, confirmed that EP3 is not involved in acid secretion in the C57BL/6 mouse, in contrast to the BALB/c mouse.

Besides the already established differences in Th1 vs. Th2, our observations identify a new dichotomy of host-specific differences between BALB/c and C57BL/6 strains that may explain different patterns of H. pylori colonization and gastritis in this model. The association of Th2 with PGE2 may not be the only explanation for the reported strain differences in Helicobacter-induced gastritis. It has been shown in mice that the relatively alkaline epithelial surface pH of the stomach is acidified by indomethacin, and this was reversed by a PGE2 analog (2). This prostaglandin-mediated alkalization of the luminal surface plays a critical role in the stimulation of gastrin and subsequent increase in acid. We propose that, in C57BL/6 mice, such a mechanism does not exist and that Helicobacter-induced prostaglandins do not increase surface pH, preventing this physiological acid increase. This compromised secretory ability of the oxyntic mucosa facilitates colonization by the bacterium, with spread of subsequent inflammation, resulting in a reduction of parietal cells, leading to atrophic gastritis. We believe that local acid production, related to the genetically determined difference in prostaglandin response described here, is responsible for the impairment of secretory function in animal models as well as, perhaps, clinically. In addition, strain-specific differences between BALB/c and C57BL/6 mice, irrespective of Th cell responses and attributed to the genetic background, have been shown in antigen-induced pulmonary eosinophilia (26) and the immune responses to pulmonary Mycobacterium bovis infection (36).

The mechanisms by which NSAIDs might cause different effects depending on the host could also be explained by our present observations. In BALB/c mice, as prostaglandin levels are inhibited by NSAIDs, this might result in the loss of a natural antisecretory mechanism and, subsequently, an increase in acid secretion, leading to mucosal injury. In C57BL/6 mice, fluctuations of prostaglandin levels do not result in modulation of net acid output, because in our experiments PGE2 does not play a role in the inhibition of acid in this strain. Hence, BALB/c mice should be more prone to NSAID-induced, acid-driven mucosal damage than "prostaglandin-blind" C57BL/6 mice. We previously performed experiments with NSAIDs in mice and observed strain-specific differences in gastric and, especially, duodenal damage (unpublished data). Contrasting differences in basal acid output have been reported among healthy volunteers after indomethacin administration, suggesting that endogenous prostaglandins play an antisecretory role in some more than others (9). Thus a similar mechanism, which relies on the differences in antisecretory response to prostaglandins described here, may also exist in the clinical setting and may be responsible for the observed variability in NSAID-related gastric adverse effects. Therefore, we suggest that identification of genetic markers that are linked to eicosanoid biology might predict individuals at risk of NSAID injury, which would be of clinical importance for our aging population.

In summary, we have shown that strain-specific differences in the physiology of acid secretion related to prostaglandins exist and that these differences can be studied in the mouse model, leading to a better understanding of the role of eicosanoids in H. pylori infection and NSAID-induced gastropathies.

ACKNOWLEDGMENTS

We thank Dr. David R. Scott for expertise in generating RT-PCR data regarding the EP3 receptor in mice.

FOOTNOTES


Address for reprint requests and other correspondence: R. H. Hunt, Div. of Gastroenterology, McMaster Univ., Health Sciences Centre, Rm. 4W8A, 1200 Main St. West, Hamilton, ON, Canada L8N 3Z5 (E-mail: huntr{at}mcmaster.ca)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

REFERENCES

  1. Austin SC and Funk CD. Insight into prostaglandin, leukotriene, and other eicosanoid functions using mice with targeted gene disruptions. Prostaglandins Other Lipid Mediators 58: 231–252, 1999.[CrossRef][ISI][Medline]
  2. Baumgartner HK, Kirbiyik U, Coskun T, Chu S, and Montrose MH. Endogenous cyclooxygenase activity regulates mouse gastric surface pH. J Physiol 544: 871–882, 2002.[Abstract/Free Full Text]
  3. Berglindh T. Gastric glands and cells: preparation and in vitro methods. Methods Enzymol 192: 93–107, 1990.[Medline]
  4. Borelli F, Welsh NJ, Sigthorsson G, Simpson R, Palizban A, Bjarnason, and Tavares IA. Gastric acid secretion in cyclooxygenase-1 deficient mice. Aliment Pharmacol Ther 14: 1365–1370, 2000.[CrossRef][ISI][Medline]
  5. Chae BS. Comparative study of the endotoxemia and endotoxin tolerance on the production of Th cytokines and macrophage interleukin-6: differential regulation of indomethacin. Arch Pharmacol Res (Seoul) 25: 910–916, 2002.
  6. Choquet A, Magous R, and Bali JP. Gastric mucosal endogenous prostanoids are involved in the cellular regulation of acid secretion from isolated parietal cells. J Pharmacol Exp Ther 266: 1306–1311, 1993.[Abstract]
  7. Danon SJ, O'Rourke JL, Moss ND, and Lee A. The importance of local acid production in the distribution of Helicobacter felis in the mouse stomach. Gastroenterology 108: 1386–1395, 1995.[ISI][Medline]
  8. Dial EJ, Hall LR, Romero JJ, Lechago J, Fox JG, and Lichtenberger LM. Altered gastrin regulation in mice infected with Helicobacter felis. Dig Dis Sci 45: 1308–1314, 2000.[CrossRef][ISI][Medline]
  9. Feldman M and Colturi TJ. Effect of indomethacin on gastric acid and bicarbonate secretion in humans. Gastroenterology 87: 1339–1343, 1984.[ISI][Medline]
  10. Fox JG, Li X, Cahill RJ, Andruits K, Rustgi AK, Odze R, and Wang TC. Hypertrophic gastropathy in Helicobacter felis-infected wild-type C57BL/6 mice and p53 hemizygous transgenic mice. Gastroenterology 110: 155–166, 1996.[ISI][Medline]
  11. Ishikawa TO, Tamai Y, Rochelle JM, Hirata M, Namba T, Sugimoto Y, Ichikawa A, Narumyia S, Taketo MM, and Seldin MF. Mapping of the genes encoding mouse prostaglandin D, E, and F and prostacyclin receptor. Genomics 32: 285–288, 1998.[CrossRef]
  12. Jaramillo E, Mårdh K, Green K, Person B, Rubio C, and Aly A. The effect of arachidonic acid and its metabolites on acid production in isolated human parietal cells. Scand J Gastroenterol 24: 1231–1237, 1989.[ISI][Medline]
  13. Kamradt AE, Greiner M, Ghiara P, and Kaufman SHE. Helicobacter pylori infection in wild-type and cytokine-deficient C57BL/6 and Balb/c mouse mutants. Microbes Inf 2: 593–597, 2000.[CrossRef][ISI]
  14. Kennedy BP, Payette P, Mudgett J, Vadas P, Pruzanski W, Kwan M, Tang C, Rancourt DE, and Cromlish WA. A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J Biol Chem 270: 22378–22385, 1995.[Abstract/Free Full Text]
  15. Kuroda E and Yamashita U. Mechanisms of enhanced macrophage-mediated prostaglandin E2 production and its suppressive role in Th1 activation in Th2-dominant Balb/c mice. J Immunol 170: 757–764, 2003.[Abstract/Free Full Text]
  16. Lands WE. The biosynthesis and metabolism of prostaglandins. Annu Rev Physiol 41: 633–652, 1979.[CrossRef][ISI][Medline]
  17. Langenbach R, Loftin C, Lee C, and Tiano H. Cylooxygenase knockout mice—models for elucidating isoform-specific functions. Biochem Pharmacol 58: 1237–1246, 1999.[CrossRef][ISI][Medline]
  18. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Maler JF, Davis BJ, and Lee CA. Disruption of mouse cylooxygenase 1 gene. Characteristics of the mutant and areas of future study. Adv Exp Med Biol 407: 87–92, 1997.[ISI][Medline]
  19. Lee A, Dixon MF, Danon SJ, Kuipers E, Mégraud F, Larsson H, and Mellgård B. Local acid production and Helicobacter pylori: a unifying hypothesis of gastroduodenal disease. Eur J Gastroenterol Hepatol 7: 461–465, 1995.[ISI][Medline]
  20. Lee A, O'Rourke J, Corazon de Ungria M, Robertson B, Daskalopoulos G, and Dixon MF. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 112: 1386–1397, 1997.[ISI][Medline]
  21. Mardh S, Norberg L, Ljungstrom M, Wollert S, Nyren O, and Gustavsson S. A method for in vitro studies on acid formation in human parietal cells. Stimulation by histamine, pentagastrin and carbachol. Acta Physiol Scand 123: 349–354, 1985.[ISI][Medline]
  22. Miyake K, Tsukui T, Wada K, Tatsuguchi A, Futagami S, Hiratsuka T, Shinoki K, Iizumi T, Akamatsu T, Sakamoto C, and Kobayashi M. Irritant-induced cyxooxygenase-2 is involved in the defense mechanism of the gastric mucosa in mice. J Gastroenterol 37: 164–171, 2002.[CrossRef][ISI][Medline]
  23. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, Akamatsu T, and Kasuga M. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterologist 112: 387–397, 1997.
  24. Mohammadi M, Czinn S, Redline R, and Nedrud J. Helicobacter-specific cell-mediated immune responses display a predominant Th1 phenotype and promote delayed-type hypersensitivity response in the stomachs of mice. J Immunol 156: 4729–4738, 1996.[Abstract/Free Full Text]
  25. Morimoto K, Sugimoto Y, Katsuyama M, Oida H, Tsuboi K, Kishi K, Kinoshita Y, Negishi M, Chiba T, Narumiya S, and Ichikawa A. Cellular localization of mRNAs for prostaglandin E receptor subtypes in mouse gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol 272: G681–G687, 1997.[Abstract/Free Full Text]
  26. Morokata T, Ishikawa J, Ida K, and Yamada T. C57BL/6 mice are more susceptible to antigen-induced pulmonary eosinophilia than Balb/c mice, irrespective of systemic T helper 1/T helper 2 responses. Immunology 98: 345–351, 1999.[CrossRef][ISI][Medline]
  27. Ottlecz A, Romero JJ, and Lichtenberger LM. Helicobacter infection and phospholipase A2 enzymes: effect of Helicobacter felis-infection on the expression and activity of sPLA2 enzymes in mouse stomach. Mol Cell Biochem 221: 71–77, 2001.[CrossRef][ISI][Medline]
  28. Padol IT and Hunt RH. The effect of Th1 cytokines on acid secretion in pharmacologically characterized mouse gastric glands. Gut 53: 1075–1081, 2004.[Abstract/Free Full Text]
  29. Sakagami T, Dixon M, O'Rourke J, Howlett R, Alderuccio F, Vella J, Shimoyama T, and Lee A. Atrophic gastric changes in both Helicobacter felis and Helicobacter pylori infected mice are host dependent and separate from antral gastritis. Gut 39: 639–648, 1996.[Abstract]
  30. Samuelson LC and Hinkle KL. Insights into the regulation of gastric acid secretion through analysis of genetically engineered mice. Annu Rev Physiol 65: 383–400, 2003.[CrossRef][ISI][Medline]
  31. Shay H, Sun DCH, and Gruenstein M. A quantitative method for measuring spontaneous gastric secretion in the rat. Gastroenterology 26: 906–913, 1954.[ISI][Medline]
  32. Suzuki K, Araki H, Mizoguchi H, Furukawa O, and Takeuchi K. Prostaglandin E inhibits indomethacin-induced gastric lesions through EP-1 receptors. Digestion 63: 92–101, 2001.[CrossRef][ISI][Medline]
  33. Taketo M, Rochelle JM, Sugimoto Y, Namba T, Honda A, Negishi M, Ichikawa A, Narumiya S, and Seldin MF. Mapping of the genes encoding mouse thromboxane A2 receptor and prostaglandin E receptor subtypes EP2 and EP3. Genomics 19: 585–588, 1994.[CrossRef][ISI][Medline]
  34. Tsai BS, Keith RH, Perkins WE, Walsh RE, Anglin CP, Collins PW, Gasiecki AW, Bauer RF, Jones PH, and Gaginella TS. Preferential binding of the novel prostaglandin SC-46275 to canine gastric versus intestinal receptors. J Pharmacol Exp Ther 275: 368–373, 1995.[Abstract]
  35. Van Doorn NEM, Namavar F, Sparrius M, Stoof J, van Rees EP, van Doorn LJ, and Vandenbroucke-Grauls CMJE. Helicobacter pylori-associated gastritis in mice is host and strain specific. Infect Immun 67: 3040–3046, 1999.[Abstract/Free Full Text]
  36. Wakeham J, Wang J, and Xing Z. Genetically determined disparate innate and adaptive cell-mediated immune responses to pulmonary Mycobacterium bovis BCG infection in C57BL/6 and Balb/c mice. Infect Immun 68: 6946–6953, 2000.[Abstract/Free Full Text]
  37. Wang TC, Goldenring JR, Dangler C, Ito S, Mueller A, Jeon WK, Koh TJ, and Fox JG. Mice lacking secretory phospholipase A2 show altered apoptosis and differentiation with Helicobacter felis infection. Gastroenterology 114: 675–689, 1998.[ISI][Medline]
  38. Yokotani K, Okuma Y, and Osumi Y. Inhibition of vagally mediated gastric acid secretion by activation of central prostanoid EP3 receptors in urethane-anaesthetized rats. Br J Pharmacol 117: 653–656, 1996.[ISI][Medline]




This Article
Abstract
Full Text (PDF)
All Versions of this Article:
288/6/G1110    most recent
00364.2004v1
Alert me when this article is cited
Alert me if a correction is posted
Citation Map
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Google Scholar
Articles by Padol, I. T.
Articles by Hunt, R. H.
Articles citing this Article
PubMed
PubMed Citation
Articles by Padol, I. T.
Articles by Hunt, R. H.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.